Matches 201 - 250 out of 263 < 1 2 3 4 5 6 >
Match Document Document Title
5601825 Therapeutic conjugates of toxins and drugs  
Provided are conjugates useful in cancer or infectious disease therapy. The conjugate is a drug or modified toxin which is a native toxin devoid of a functioning receptor binding domain and a...
5597569 Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica  
The present invention discloses a new ribosome-inactivating protein, bryodin 2, isolated from the plant Bryonia dioica. This ribosome-inactivating protein (RIP) is a type IRIP having a single...
5587162 Treatment of allograft rejection with IL-2 receptor-specific cytotoxins  
Methods of inhibiting the rejection and prolonging the survival of an allograft in a mammal are provided. The methods involve administering to the mammal a cytotoxin-conjugated IL-2...
5578706 Methods and compositions concerning homogenous immunotoxin preparations  
Immunotoxin preparations are described in which the preparations are enriched for a single species of immunotoxin. Also described are methods for the preparation of the substantially purified...
5561119 Glycosylated prodrugs, their method of preparation and their uses  
Glycosylated prodrugs, a preparation method therefor, and their use with tumor-specific immunoenzymatic conjugates for the treatment of cancer, are described. These anthracycline prodrugs have...
5512658 Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids  
Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive...
5455030 Immunotheraphy using single chain polypeptide binding molecules  
The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy...
5453271 Vaccine against ricin toxin  
It is now possible to immunize susceptible mammals against the pathological effect of exposure to rice, including inhalation of ricin, by administration of an immunogenic effective amount of ricin...
5435990 Macrocyclic congugates and their use as diagnostic and therapeutic agents  
A group of functionalized macrocyclic polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes, covalently attached to an antibody or antibody...
5358710 Method for the suppression of an immune response  
A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the...
5352447 Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy  
A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against...
5326559 Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules  
The invention features a method for treating a patient suffering from accelerated atherosclerosis in a patient suffering from vascular damage, e.g., damage caused by percutaneous transluminal...
5277894 Method for tumor detection and treatment  
The invention relates to a method of detecting an Fc receptor-expressing tumor site in an individual by administering to the individual a diagnostically effective amount of detectably-labeled...
5208008 Regioselective chemical modification of monoclonal antibodies  
A method of selectively modifying an immunoglobulin having at least one Fab region and at least one Fc region, each region having an isoelectric point wherein said isoelectric point of the Fab...
5183756 Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same  
The present invention relates to the monoclonal antibody (termed D612) having selective reactivity for gastrointestinal carcinoma and methods for employing the same. A hybridoma producing such...
5149528 Cytotoxic protein from Trichosanthes kirilowii  
Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline...
5116944 Conjugates having improved characteristics for in vivo administration  
Conjugates comprising a therapeutically effective proteinaceous active moiety linked to an albumin moiety which exhibit enhanced serum half-life and stability properties are disclosed. The...
5093117 Compositions and method for the treatment or prophylaxis of sepsis or septic shock  
Pharmaceutical compositions useful for the treatment or prophylaxis of Gram-negative bacteremia or septic shock contain a bactericidal effective amount of polyclonal immunoglobulins against...
5091177 Monoclonal antibodies for treatment of human non-small cell lung carcinomas  
The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human...
5055291 Compositions for preventing secondary cataracts  
Novel methods and compositions are provided for preventing secondary cataracts. A cytotoxic agent is employed which is introduced into the anterior chamber of the eye to inhibit proliferation of...
5053491 Monoclonal antibodies and cell lines for parathyroid tissue-specific antigen  
Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind...
5003046 Monoclonal antibody producing hybridoma and corresponding antibody specific for human breast fibroblast tumor antigen  
The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin,...
4971792 Monoclonal antibodies against glycolipid antigens  
The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.
4962189 Ribotoxin conjugates  
The invention herein is directed to methods using Procion dyes to perform separations of interest in manipulating the NAD + -independent ribotoxins. The methods are useful for preparing...
4962188 Recombinant ricin toxin A chain conjugates  
Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab') 2 fragments of...
4958009 Anti-human ovarian cancer immunotoxins and methods of use thereof  
Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID 50 of 10...
4950713 Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals  
Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.
4946943 Purification of ribotoxins and their conjugates  
The invention herein is directed to methods using Procion dyes to perform separations of interest in manipulating the NAD + -independent ribotoxins. The methods are useful for preparing...
4939083 Carbohydrate specific to chronic myelogenous leukemia granulocytes  
A substantially purified carbohydrate is provided which is isolated from chronic myelogenous leukemia cells. The carbohydrate is immunogenic and can be utilized to raise both polyclonal and...
4925661 Target-specific cytotoxic liposomes  
The A fragment of the diphtheria toxin (DTA) was encapsulated in pH-sensitive liposomes. This novel reagent is extremely cytotoxic to cells expressing surface antigen which is recognized by the...
4925922 Potentiation of cytotoxic conjugates  
Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on...
4916213 Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof  
Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on...
4911690 Treatment or diagnosis by endoscopic administration into the lymphatics  
The invention provides a method of delivering therapeutic or diagnostic reagents to the lymphatic system. In the preferred method the delivery is accomplished by use of a fiberoptic endoscope...
4906452 Trichothecene conjugates and methods of use  
Conjugates of trichothecenes and agents that bind to a defined population of cells are disclosed. Preferred are conjugates of trichothecene molecules with polyclonal or monoclonal antibodies or...
4906469 Appropriate cytotoxic pharmaceutical combination especially for the treatment of cancers  
The invention relates to a cytotoxic pharmaceutical combination comprising: at least a first antibody possessing the capacity of selective recognition of a target antigen or antigens carried by...
4904481 Method of conferring immuno-tolerance to a specific antigen  
A method of selectively suppressing the immune system and conferring immunotolerance against a specific antigen by interferring with the L3T4 differentiation antigens on helper T cells is...
4902495 IgE Fc directed delivery system  
An immunotoxin comprising a conjugate of a toxin with immunoglobulin E or a part thereof and a method delivering the same to a target site is described. Mast cell related abnormalities can be...
4894225 Combination therapy using antitumor immunotoxins with tumor necrosis factor  
Tumor necrosis factor and a suitable immuotoxin when administered simultaneously or in tandem produce a synergistic effect in treating tumor burden in warm-blooded animals. Methods and protocols...
4894227 Composition of immunotoxins with interleukin-2  
Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one immunotoxin that binds selectively to...
4892827 Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects  
Modified Pseudomonas exotaxins which comprise deletions in at least domain 1A are taught. The toxins exhibit reduced cytotoxicity.
4867962 Functionally specific antibodies  
Diagnostic or therapeutic agents are attached to two or more antibody species having non-overlapping patterns of cross-reactivity to increase the relative amount of the active agent(s) delivered to...
4863726 Combination therapy using immunotoxins with interleukin-2  
Anti-tumor activity in humans can be augmented by administering to the mammalian host a pharmacologically effective amount of mammalian IL-2 and at least one immunotoxin that binds selectively to...
4863729 Method for preparing a macromolecular monoclonal antibody composition  
Macromolecular monoclonal antibody compositions are provided which are capable of selectively forming stable bonds to cells having a predetermined concentration of at least one surface antigen,...
4861579 Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies  
Selective suppression of B-lymphocytes in mammals is accomplished by treatment with an adequate amount of antibody to a mature B-lymphocyte surface marker.
4831117 Monoclonal antibody specific for human B-cells  
A hybrid cell line yields a monoclonal antibody which is highly restricted to B-lineage lymphoblastic leukemia cells and their progenitors.
4808705 Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor  
Highly stable pharmaceutical compositions suitable for parenteral administration to animals or humans comprising a therapeutically effective amount of an RTA-immunoconjugate dissolved in an inert...
4792447 Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors  
Highly specific antibodies directed against immunoglobulin determinants coupled to one or more toxin molecules provide antibody-toxin conjugates which are useful in selectively inhibiting the...
4771128 Method of purifying toxin conjugates using hydrophobic interaction chromatography  
A method of isolating and purifying toxin conjugates using hydrophobic interaction chromatography. Crude conjugate mixtures are sized to remove unconjugated toxin, and loaded onto a column filled...
4745180 Solubilization of proteins for pharmaceutical compositions using heparin fragments  
A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is β-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without...
4731238 Novel monoclonal hybridoma and corresponding antibody  
The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin,...
Matches 201 - 250 out of 263 < 1 2 3 4 5 6 >